Bausch + Lomb Corp faces a mixed week as investors navigate the healthcare landscape with caution.
This week, Bausch + Lomb Corp (BLCO.TO) saw a slight decline in its stock price, closing at C$24.36. This marks a drop of 1.14% for the day and 1.89% for the week. Recent company news highlights ongoing research and market perceptions that may influence investor sentiment.
Investor takeaway: While Bausch + Lomb continues to conduct research and engage with healthcare needs, its stock performance reflects broader market caution, particularly with a negative profit margin and a beta of 0.56, suggesting lower volatility compared to the market.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.72B
52W high
$25.70
52W low
$19.36
1W change
+2.39%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO · as of Oct 5, 2026
Wall Street analysts forecast BLCO stock price to rise 5.6% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.78
+5.6% Upside
Previously C$25.77 on Oct 2, 2026
Current Price
C$24.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
21.6%
Annualized
90-Day Vol
27.2%
Annualized
Trend (90d)
+12.0%
Annualized drift
90d Mean
C$25.48
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$24.76 | C$22.98 – C$26.68 |
| 60 trading days | C$25.12 | C$22.61 – C$27.91 |
| 90 trading days | C$25.48 | C$22.39 – C$29.00 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bausch + Lomb Corp's stock is down 1.89% this week.
Despite this recent decline, the stock has gained 4.19% over the past month, indicating potential recovery signals amid ongoing challenges.
Bull case
Positive developments in research and improving market sentiment could boost Bausch + Lomb's stock, especially if the company effectively addresses its negative profit margin.
Bear case
Continued market caution and concerns over profitability may hinder stock performance, particularly as the company faces challenges in the healthcare sector.
Recent Performance Overview
Advertisement
Bausch + Lomb Corp's stock closed at C$24.36, reflecting a 1.14% decline for the day and a 1.89% drop for the week. This performance contrasts with a more positive view over the past month, where the stock has appreciated by 4.19%. Year-to-date, Bausch + Lomb has shown a gain of 6.89%, indicating some resilience despite market challenges.
Company News and Catalysts
Recent headlines regarding Bausch + Lomb include the announcement of new published research on their enVista Aspire™ product, which may significantly influence market perception. Additionally, a survey revealed that many women do not recognize dry eye as a symptom of perimenopause and menopause, highlighting a growing awareness and potential market for Bausch + Lomb's products. However, caution remains as the stock trades below perceived fair value, according to some analysts.
Technical Picture
The technical indicators for Bausch + Lomb present a mixed picture. The stock is currently trading above its 50-day moving average of C$23.58 by 3.3% and above its 200-day moving average of C$22.91 by 6.3%. The 52-week range has been between C$19.36 and C$25.70, with the stock trading at approximately 79% of this range. With a beta of 0.56, Bausch + Lomb exhibits lower volatility compared to the broader market, which may appeal to more conservative investors. The latest trading volume of 1,401 shares is slightly below the 20-day average volume of 1,705 shares, indicating a decrease in trading activity.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
